Startup Claims First Patient Treated With AI-Designed Viruses
A startup says an AI-designed virus therapy has treated its first patient, targeting drug-resistant E. coli. The claim has not been peer-reviewed, and independent clinical data are still lacking.
The treatment is aimed at a type of bacteria that can resist conventional antibiotics. The New York Times described it as an experimental treatment. MIT Technology Review has reported that AI-designed viruses are already killing bacteria, but the new claim concerns a patient treatment, a further step that would require clinical evidence to assess.
The claim comes after recent work in generative biology. In 2025, Stanford University PhD student Samuel King used a generative AI model to propose genetic blueprints for microscopic viruses, MIT Technology Review reported. His work offered a preliminary answer to whether AI can design new life forms, but it was not yet an example of AI-generated life. MIT Technology Review named King one of its Innovators Under 35, and senior AI reporter James O'Donnell spoke with him in a Roundtables conversation about his work and new ways of seeing biology.
A laboratory design is not the same as a treated patient. The startup's claim, if confirmed, would mark the first reported patient treatment using viruses designed with AI. Without peer-reviewed results, however, it is not possible to verify the treatment's safety, efficacy, or how the patient responded. The New York Times report and Futurism's caveat together frame the announcement as a company claim rather than a validated clinical result.